From Evidence to Implementation: FIB-4-Based Risk Stratification for Advanced Liver Disease in Saudi Primary Care

Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly common and poses a growing challenge for health systems, because most affected people are managed outside specialist liver services. The clinically important task is not simply to identify hepatic steatosis, but to find the smaller subgroup with clinically significant fibrosis who face the greatest risk of liver-related complications and who may now be eligible for liver-directed pharmacotherapy. The fibrosis-4 index (FIB-4), calculated from age, aspartate aminotransferase, alanine aminotransferase and platelet count, has emerged as a pragmatic first-line tool for fibrosis risk stratification. Contemporary guidance recommends a stepwise approach in at-risk populations, with FIB-4 followed by second-line non-invasive testing, most commonly vibration-controlled transient elastography (VCTE) or the Enhanced Liver Fibrosis (ELF) test. The September 2026 Global NASH/MASH Council consensus consolidates this fibrosis-centred, non-invasive-test-driven model further and links second-line test thresholds to treatment initiation and response monitoring in non-cirrhotic MASH with F2–F3 fibrosis. Saudi Arabia is a particularly relevant setting given its substantial cardiometabolic burden and emerging evidence of a high MASLD prevalence. Recent Saudi data include a multicentre primary-care cohort reporting an age- and sex-adjusted MASLD prevalence of 34.2%, a real-world primary-care study demonstrating intermediate or high FIB-4 risk among metabolically high-risk patients despite normal liver enzymes, and a Saudi consensus incorporating FIB-4 into local risk stratification. Important implementation questions remain, however, including target populations, age-related interpretation, laboratory readiness, second-line testing capacity, referral pathways, treatment access, repeat assessment, electronic health-record integration and cost-effectiveness. This narrative review traces the evolution of FIB-4 from a prognostic marker to a primary-care triage tool, critically examines contemporary international and Saudi evidence, and proposes a context-sensitive framework and staged research agenda for FIB-4-based risk stratification in Saudi primary care.